These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18471768)

  • 1. Minimising moxifloxacin resistance with tuberculosis.
    Drlica K; Zhao X; Kreiswirth B
    Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of Mycobacterium bovis against moxifloxacin.
    Weiss T; Schönfeld N; Bettermann G; Blum TG; Kollmeier J; Mauch H; Bauer TT; Rüssmann H
    Int J Tuberc Lung Dis; 2012 Nov; 16(11):1562. PubMed ID: 23044455
    [No Abstract]   [Full Text] [Related]  

  • 4. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
    J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.
    Tortoli E; Dionisio D; Fabbri C
    J Chemother; 2004 Aug; 16(4):334-6. PubMed ID: 15332706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
    Malik M; Drlica K
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.
    Isaeva Y; Bukatina A; Krylova L; Nosova E; Makarova M; Moroz A
    J Antimicrob Chemother; 2013 Oct; 68(10):2274-81. PubMed ID: 23788475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
    J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 13. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
    Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
    J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiology. TB--a new target, a new drug.
    Cole ST; Alzari PM
    Science; 2005 Jan; 307(5707):214-5. PubMed ID: 15653490
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin.
    Piersimoni C; Lacchini C; Penati V; Iona E; Fattorini L; Nista D; Zallocco D; Gesu GP; Codecasa L
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):283-7. PubMed ID: 17338942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
    Nuermberger EL; Yoshimatsu T; Tyagi S; O'Brien RJ; Vernon AN; Chaisson RE; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2004 Feb; 169(3):421-6. PubMed ID: 14578218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.